Near-unicorn Prestige Biopharma eyes early-2021 IPO in South Korea
Singapore-based firm last valued at US$827m; does not say how much it is raising in IPO
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Singapore
SINGAPORE-BASED Prestige Biopharma is in the midst of pursuing an initial public offering (IPO) on the Korea Exchange, with a targeted listing in early 2021, the firm's chief executive Lisa Park said in response to queries from The Business Times (BT).
Earlier on Friday, BT reported that Prestige Biopharma's Singapore-registered entity had been been fully acquired by the Korea Securities Depository (KSD), as shown in Dec 8 regulatory data on intelligence platform VentureCap Insights.
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Singaporeans can now buy record amount of yen per Singdollar
Beijing’s calculated silence on the Iran war
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
StarHub hands Ensign InfoSecurity control back to Temasek in S$115 million deal, books S$200 million gain
